Bilirubin-IXa photooxidation products were detected by high performance liquid chromatography in the urine of neonates undergoing phototherapy for hyperbilirubinemia. The in vivo photoproducts were identified by chromatographic comparison with authentic synthetic standards using two complementary methods. Bilirubin photooxidation products were not detected in urine from jaundiced infants not receiving phototherapy. The specific photoproducts identified in the urine include propentdyopents, hematinic acid imide and its hydrolysis product (3-carboxy-2-methyl-2-hexenedioic acid), and the hydrolysis product (2-vinyl-3-methyl-maleic acid) of methylvinylmaleimide. Their total urinary concentrations were low (0.2-0.9 mg/dl) during phototherapy. These observations show that photooxidation of bilirubin clearly does occur during phototherapy. They are consistent with the view that, although photooxidation is not the major photochemical event associated with phototherapy, it can and clearly does occur concurrently with photoisomerization.
Summary
Bilirubin-IXa photooxidation products were detected by high performance liquid chromatography in the urine of neonates undergoing phototherapy for hyperbilirubinemia. The in vivo photoproducts were identified by chromatographic comparison with authentic synthetic standards using two complementary methods. Bilirubin photooxidation products were not detected in urine from jaundiced infants not receiving phototherapy. The specific photoproducts identified in the urine include propentdyopents, hematinic acid imide and its hydrolysis product (3-carboxy-2-methyl-2-hexenedioic acid), and the hydrolysis product (2-vinyl-3-methyl-maleic acid) of methylvinylmaleimide. Their total urinary concentrations were low (0.2-0.9 mg/dl) during phototherapy. These observations show that photooxidation of bilirubin clearly does occur during phototherapy. They are consistent with the view that, although photooxidation is not the major photochemical event associated with phototherapy, it can and clearly does occur concurrently with photoisomerization. Abbreviations VCB, unconjugated (4Z, 15Z)-bilirubin-IXa HPLC, high performance liquid chromatography Phototherapy is used routinely in hospitals for treating neonatal jaundice (hyperbilirubinemia). Patients are irradiated with white er blue light to enhance elimination of the yellowcytotoxic metabolite (4Z, l5Z)-bilirubin-IXa, which is produced in copious quantities in mammals by degradation of heme (2) . Under normal metabolic conditions, VCB is detoxified by conjugation in the liver and excreted in bile. When conjugation is impaired, VCB accumulates in plasma and partitions into extravascular tissues, including the brain (23) . About 150,000 infants per year in the United States develop plasma VCB levels of 15 mg/dl (3), and a large number of these receive some form of treatment (phototherapy) to remove or accelerate the excretion of VCB from the body, apparently reducing the risk of bilirubin encephalopathy (23) .
The mechanism ofVCB elimination in jaundice phototherapy has been investigated for many years. At first it was thought that the important photochemical event was accelerated catabolism of VCB to water-soluble derivatives that were excreted principally in bile and , to some extent, in urine (18) . In this connection, a considerable effort was directed toward studies of bilirubin photooxidation (7, 21) , wherein singlet oxygen, i.e. molecular oxygen in its first electronic excited state and known to be cytotoxic (25) , was thought to be the oxidizing species (7) . Recent data indicate that singlet oxygen may not be implicated and that bilirubin photooxidation may proceed via radical intermediates (6) . Mechanistic questions aside, the products of in vitro photooxidation have been well characterized (7) .
The widely held belief that bilirubin photodegradation is the responsible mechanism for lowering serum VCB in neonatal phototherapy (5) began to erode with the discovery of an apparent augmented excretion of VCB in the bile of Gunn rats (19) and jaundiced babies (10) undergoing light irradiation. This important finding was extremely intriguing because VCB normally cannot be excreted by the liver unless it is converted to polar conjugates, principally glucuronides (2) . To accommodate the confirmed (II , 21) biliary excretion, Z +Z E photochemical configurational isomerization at the mesocarbon-carbon double bonds of (4Z, 15Z)-biIirubin-IXa was proposed (7, 8) to give more polar E-isomers, isomers that could more easily cross the liver. The hypothesis was subsequentl y tested (15) and confirmed in Gunn rats (12, 24) . More recently, the structures of the Eisomers have been proved, and it has been shown that these isomers are formed in jaundiced rats exposed to blue light and in humans during phototherapy (14, 16) . At present, current evidence favors the photochemical configurational isomerization of VCB (to E-isomers) as one of the most rapidly occurring photochemical events in phototherapy.
Of what importance is VCB photodegradation, however? In early studies with Gunn rats, Ostrow (20) suggested that VCB was photo oxidized to smaller, more polar, water-soluble degradation products such as mono-and dipyrroles that were easily excreted. In support of that proposal, DCB photooxidation in vitro was examined, and many water-soluble photodegradation products were separated and characterized (7, 8) . There is no conclusive evidence supporting the occurrence ofDCB photooxidation in vivo during phototherapy, and no specific photooxidation products have been isolated and identified. Callahan et of. (3) reported the presence of polar, predominantly diazonegative VCB photoproducts in bile and urine of congenitally jaundiced (Crigler-Najjar) infants undergoing phototherapy, but none of the products were identified. Ostrow (19) also reported finding VCB photoproducts in the bile and urine of (congenitally jaundiced) Gunn rats exposed to daylight fluorescent light. These, too, were not identified. Significantly, however, the Gunn rat urine gave a positive pentdyopent reaction following phototherapy, suggesting the presence of dipyrroles. Later, Onishi et al. (17) apparently found VCB photooxidation products in the
R=CH 3 : . HPLC (silica column) scans of urina ry products. Top, sample takend h after birth and before the onset of phototherapy. There are essentially no UCB photooxygenation products detected in this voiding. Middle, sample taken after 4 h into an 8-h photothe rapy session. A dramatic growth of photoproducts is observed. Bottom , sample taken approximately 18 h after cessation of phototherapy. The infant is still voiding small amounts of UCB photooxygenation products. The intense unknown peak at 8.25 min serves as a convenient internal reference by which one can gauge the dramatic increase in UCB photoproducts during phototherapy. Arrows indicate the expected positions of the various standards, a-h of Figure I. blood, urine, and stools of "bronze" babies. Using HPLC, the y found two prominent peaks in the uri ne, one corresponding to a tet rapyrrole, the other to a polymer. Apart from these early findings , no firm experimental evidence for UCB photooxidation during neonatal phototherapy has been published.
Although photoisomerization is held to be the major photochemical mechanism in vivo (5) , continuous irradiation must unavoidabl y lead to som e photooxidation (13) . This being so, it seemed likely to us that such (polar, lower molecular weight) photoproducts would be excreted in urine. We ha ve therefore analyzed urin e sam ples from jaundiced infants undergoing phototherapy using newly developed, sensitive chromatographic techniques and well-charac terized chemical standards th at were not available to pre vious investigators. Ou r results show clearly that some photooxidation ofUCB does occur during phototherapy.
MATERIALS AND METHODS
Urine was collected (protected from light) from six jaundiced infa nts undergoing phototherapy and three jaundiced control infants not receiving phototherapy. The initial voidi ng was frozen as soon as possible and stored in the dark. Each additional voiding for that infant was added to th e previously frozen voids until eith er phototherapy was discontinued or for about 12 h for the controls. The gestational ages of the infants undergoing phototherapy ranged from 27 to 39 weeks (with birth weights of 880-3 180 g), and those of the controls ranged from 26 weeks to term (with birth weights of 845-2860 g). Eight were premature. Serum UCB levels of infants undergoing phototherapy ranged from 5.5 to 13.4 mg/dl; those of the controls rang ed from 3-8.6 mg/dl, One infant was studied before, during, and after phototherapy. One term infant with conjugated hyperbilirubinemia (6.9 mg/dl direct reacting), who exhibited a positi ve urine diazo reaction and was not under phototherapy, was also studied.
The samples were lyophilized, and the residue was.methylated in excess ethereal-meth anolic diazomethane to form methyl esters of any existing carboxylic acid containing photoproducts and, at the same time , methanolyze an y water-propentdyopents present (9) . The solvent was rapidly evaporated and the residue was analyzed by a Perkin-Elmer Series 3 analytical HPLC equ ipped with: 1) a DuPont column (25 em x 4.6 mm ID) pack ed with Zorbax-Sil 7-1l silica using an isocratic eluent of 1% acetic acid in Fisher HPLC grade chloroform (flow, 1.0 ml/rnin; pressure 4-5.6 mPa; detector, 280 nm), and 2) a Kn auer reverse phase column (25 em x 4.6 mm 10) packed with 5-1lODS-CI8
and an isocratic eluent of 26.9% Fisher HPLC grade acetonitrile inpurified water (flow, 1.0 ml/min; pressure, 3.2 mPa; detector, 280 nm). The HPLC analysis of a given sample invol ved dissolving on e-half of the methylated urinary material in 2.0 ml of chloroform (for th e silica column) and the remaining half in acetonitrile (for th e reverse phase column). The sample solutions (25 Ill) were injected on the appropriate column. For coinjection stud ies with UCB photooxidation standards (see below), the standards were dissolved in enough solvent to give 5 mg/dl concentrations. A sample (25 Ill) of standards solution was injected first and then followed with an injection of a mixture of 25 III of standards solution + 5 III of urinary sample. As many standard solutions (5 III each) were coinjected as necessary for clarification and identification of th e urinary sample components.
Reference standards were synthesized by photooxidation of bilirubin-IXa (Sigma) in methanolic ammonia ( 1%) followed by rap id diazomethane methylation in the same mann er as abo ve (9) . The standards were purifi ed using preparative HPLC on a high flow DuPont column (50 em x 25 mm 10) packed with 20
Lichrospheres coated with silica. The structures of the separated standard UCB photoox idation products were confirmed by comparison with prev iously reported reference standards (7, 8) and by the ir 100 MHz IH NMR spectra obtained from a lEaL FX-100 instrument. A sample of the dipyrrole dialdehyde was provided by Dr. A. F. McDonagh, School of Medicine, University of California, San Francisco. The eight reference standards (7, 8) (shown in Fig. I ) include: the dimethyl ester of the hydrolysis product of methylvinylmaleimide (HPLC peak a), the trimethyl ester of the hydrolysis product of hematinic acid (HPLC peak b), hematinic acid methyl ester (H PLC peak c), methylvinylmal-. eim ide (HPLC peak d), dipyrrole dialdehyde dimethyl ester (HPLC peak e), exovinyl-B-methanol propentdyopent methyl ester (HPLC peak f) , exovinyl-Asmethanol propentdyopent methyl ester (HPLC peak g), and endovinyl-B-methanol propentdyopent methyl ester (HPLC peak h).
Initially , a standard reference profile was obtained by injecting the reference standards into the HPLC in order to identify retention times (Fig. 2) . Samples obtained from urine were then injected, and their components were matched with the reference standards by I) comparison of retention times and 2) coinjection. The coinjection procedure served two useful purposes: I) to establish a high degree of confidence that an "unknown" peak in the urine sample corresponds exactly with a reference standard by coinjection on both the silica column and the reverse phase column, and 2) to allow for direct calculations of the VCB photooxidation products in the urine samples by coinjection with reference standards of known concentration and volume.
RESULTS
Successful HPLC separation of all eight VCB photooxidation standards (Fig. 1, a-h ) is shown in Figure 2 . Only methylvinylmaleimide (d) failed to appear on the silica column, because it decomposed in the solvent system used (chloroform-I % acetic acid). Validity of analysis was checked using synthetic mixtures of a-h). We could correctly detect and anal yze for the components of the synthetic mixtures by coinjection of individual standards. Thus, it seemed likely that we could detect any of the known bilirubin photooxidation products A-H) should they appear in urine. The probability of correct matching and identification was increased by using two fundamentally different HPLC columns (with appropriate elution solvents): silica, for adsorption chromatography, and ODS-CI8 for reverse phase or partition chromatography. Consequently, it is extremely unlikely that an unknown urinary component different from a given standard would show chromatographic behavior identical to the standard in both systems.
. Typical HPLC scans to analyze for the presence of VCB photooxidation products in urine are presented in Figure 3 . Analysis of methylated materials from urine taken from a neonate before, during, and after phototherapy is shown. The urine sample collected prior to phototherapy showed essentially none of the standards, either on a silica column (Fig. 3, top) or on a reverse phase column. Only trace amounts of the derivatized hydrolysis products of both methylvinylmaleimide and hematinic acid imide, a and b, respectively, and hematinic acid imide (c) were found. On the other hand, a urine sample collected after 4 h of phototherapy, when the serum VCB was 10.3 mgjdl, clearly shows the presence ofVCB photooxidation products (Fig.   3, middle) . The peaks for a, b, and c are markedly enhanced and new strong peaks appear for two propentdyopents,fand h. (N.B.:
the unknown intense peak at 8.25 min retention time may be used as an internal standard in all HPLC scans of Fig. 3 .) The same photoproducts persisted to some extent (Fig. 3, bottom) up to 18 h after cessation of light therapy. Similar results for five other jaundiced infants with unconjugated hyperbilirubinemia and undergoing phototherapy are presented in Table 1 along with three control jaundiced patients with unconjugated hyperbilirub inemia and not undergoing phototherapy.
Vrine samples from a neonate with conjugated hyperbilirubinemia (6.9 mg/dl) and not under lights showed (HPLC) no detectable amounts of any of the dipyrroles (E-H) and only a trace of hematinic acid imide (C), this with HPLC injection volumes three times greater than standard.
The concentrations of the various VCB photooxidation products (Fig. I) found in urine and analyzed as their methylated derivatives are also given in Table I . The concentrations were determined by measuring HPLC peak areas and comparing them with the peak areas from sample + standard coinjections.
DISCUSSION
These studies provide the first clear, qualitative analytical proof that VCB photooxidation products (propentdyopents F and H), hematinic acid imide C, its hydrolysis product B, and the hydrolysis product of methylvinylmaleimide A ; Fig. 1 ) appear in the urine during phototherapy of human neonates with unconjugated hyperbilirubinemia (Table 1 ). The cited photooxidation products either do not arise or, as with the monopyrrole derivatives, occur to a lesser extent in jaundiced babies not undergoing phototherapy. And , except for a trace amount of hematinic acid imide (C) detected as its methyl ester (c) , none of the VCB photodegradation products of Fig. I could be found in the urine of a full term baby with unconjugated hyperbilirubinemia not under phototherapy. We speculate that the origin of small quantities of hematinic acid imide (C), its hydrolysis product (B) , and the hydrolysis product of methylvinylmaleimide (A) mayoriginate from VCB or its metabolic precursors via enzymatic oxidations (22, 23) . Finding the hydrolysis product of methylvinylmaleimide (A) in urine is probably evidence for formation of its precursor imide despite our failure to detect any D. However, methylvinylmaleimide (D) is known to be unstable and may not survive long in vivoor during the experimental processing of the urine. The expected dipyrrole dialdehyde (E) and propentdyopent (G) were not found. The former may be formed in only extremely small amounts, much as it is apparently during in vitro bilirubin photooxidation (1), and below our threshold detection level. It is also unclear why the pentdyopent G should not be found, especially when the isomeric propentdyopents F and H are. It may be that neither E nor G is formed at all.
The amounts (Table 1) of renally excreted UCB photooxidation products are small, in keeping with the distribution of excreted label following administration of [I4C]UCB and light irradiation (19) . If we assume also that only small amounts are formed in vivo, then our studies support the belief (5) that alternative photochemical pathways, e.g. configurational isomerization, are of greater importance in phototherapy. The studies demonstrate that UCB photooxidation occurs in vivo and is a component of phototherapy. And they identify for the first time known bilirubin photooxidation products in vivo.
